Cargando…

Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value

BACKGROUND: Immunohistochemical assessment of proliferation may provide additional prognostic information in early breast cancer. However, due to a lack of methodological standards proliferation markers are still not routinely used for determining therapy. Even for Ki67, one of the most widely-studi...

Descripción completa

Detalles Bibliográficos
Autores principales: Joshi, Shalaka, Watkins, Johnathan, Gazinska, Patrycja, Brown, John P., Gillett, Cheryl E., Grigoriadis, Anita, Pinder, Sarah E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513675/
https://www.ncbi.nlm.nih.gov/pubmed/26205655
http://dx.doi.org/10.1186/s12885-015-1531-3
_version_ 1782382678375399424
author Joshi, Shalaka
Watkins, Johnathan
Gazinska, Patrycja
Brown, John P.
Gillett, Cheryl E.
Grigoriadis, Anita
Pinder, Sarah E.
author_facet Joshi, Shalaka
Watkins, Johnathan
Gazinska, Patrycja
Brown, John P.
Gillett, Cheryl E.
Grigoriadis, Anita
Pinder, Sarah E.
author_sort Joshi, Shalaka
collection PubMed
description BACKGROUND: Immunohistochemical assessment of proliferation may provide additional prognostic information in early breast cancer. However, due to a lack of methodological standards proliferation markers are still not routinely used for determining therapy. Even for Ki67, one of the most widely-studied markers, disagreements over the optimal cutoff exist. Improvements in digital microscopy may provide new avenues to standardise and make data more reproducible. METHODS: We studied the immunohistochemical expression of three markers of proliferation: Ki67, Mini-Chromosome Maintenance protein 2 and Geminin, by conventional light microscope and digital imaging on triplicate TMAs from 309 consecutive cases of primary breast cancers. Differences between the average and the maximum percentage reactivity in tumour cell nuclei from the three TMA cores were investigated to assess the validity of the approach. Time-dependent Receiver Operating Characteristic curves were utilized to obtain optimal expression level cut-offs, which were then correlated with clinico-pathological features and survival. RESULTS: High concordance between conventional and digital scores was observed for all 3 markers (Ki67: r(s) = 0.87, P < 0.001; MCM2: r(s) = 0.94, P < 0.001; and Geminin: r(s) = 0.86, P < 0.001; Spearman’s rank). There was no significant difference according to the number of TMA cores included for either Ki67 or MCM2; analysis of two or three cores produced comparable results. Higher levels of all three proliferation markers were significantly associated with higher grade (P < 0.001) and ER-negativity (P < 0.001). Optimal prognostic cut-offs for percentage expression in the tumour were 8 %, 12 and 2.33 % for Ki67, MCM2 and Geminin respectively. All 3 proliferation marker cutoffs were predictive of 15-year breast cancer-specific survival in univariable Cox regression analyses. In multivariable analysis only lymph node status (HR = 3.9, 95 % CI = 1.79-8.5, P = 0.0006) and histological grade (HR = 1.84, 95 % CI = 1–3.38, P = 0.05) remained significantly prognostic. CONCLUSIONS: Here we show that. MCM2 is a more sensitive marker of proliferation than Ki67 and should be examined in future studies, especially in the lymph node-negative, hormone receptor-positive subgroup. Further, digital microscopy can be used effectively as a high-throughput method to evaluate immunohistochemical expression. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1531-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4513675
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45136752015-07-25 Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value Joshi, Shalaka Watkins, Johnathan Gazinska, Patrycja Brown, John P. Gillett, Cheryl E. Grigoriadis, Anita Pinder, Sarah E. BMC Cancer Research Article BACKGROUND: Immunohistochemical assessment of proliferation may provide additional prognostic information in early breast cancer. However, due to a lack of methodological standards proliferation markers are still not routinely used for determining therapy. Even for Ki67, one of the most widely-studied markers, disagreements over the optimal cutoff exist. Improvements in digital microscopy may provide new avenues to standardise and make data more reproducible. METHODS: We studied the immunohistochemical expression of three markers of proliferation: Ki67, Mini-Chromosome Maintenance protein 2 and Geminin, by conventional light microscope and digital imaging on triplicate TMAs from 309 consecutive cases of primary breast cancers. Differences between the average and the maximum percentage reactivity in tumour cell nuclei from the three TMA cores were investigated to assess the validity of the approach. Time-dependent Receiver Operating Characteristic curves were utilized to obtain optimal expression level cut-offs, which were then correlated with clinico-pathological features and survival. RESULTS: High concordance between conventional and digital scores was observed for all 3 markers (Ki67: r(s) = 0.87, P < 0.001; MCM2: r(s) = 0.94, P < 0.001; and Geminin: r(s) = 0.86, P < 0.001; Spearman’s rank). There was no significant difference according to the number of TMA cores included for either Ki67 or MCM2; analysis of two or three cores produced comparable results. Higher levels of all three proliferation markers were significantly associated with higher grade (P < 0.001) and ER-negativity (P < 0.001). Optimal prognostic cut-offs for percentage expression in the tumour were 8 %, 12 and 2.33 % for Ki67, MCM2 and Geminin respectively. All 3 proliferation marker cutoffs were predictive of 15-year breast cancer-specific survival in univariable Cox regression analyses. In multivariable analysis only lymph node status (HR = 3.9, 95 % CI = 1.79-8.5, P = 0.0006) and histological grade (HR = 1.84, 95 % CI = 1–3.38, P = 0.05) remained significantly prognostic. CONCLUSIONS: Here we show that. MCM2 is a more sensitive marker of proliferation than Ki67 and should be examined in future studies, especially in the lymph node-negative, hormone receptor-positive subgroup. Further, digital microscopy can be used effectively as a high-throughput method to evaluate immunohistochemical expression. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1531-3) contains supplementary material, which is available to authorized users. BioMed Central 2015-07-25 /pmc/articles/PMC4513675/ /pubmed/26205655 http://dx.doi.org/10.1186/s12885-015-1531-3 Text en © Joshi et al. 2015 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Joshi, Shalaka
Watkins, Johnathan
Gazinska, Patrycja
Brown, John P.
Gillett, Cheryl E.
Grigoriadis, Anita
Pinder, Sarah E.
Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value
title Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value
title_full Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value
title_fullStr Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value
title_full_unstemmed Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value
title_short Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value
title_sort digital imaging in the immunohistochemical evaluation of the proliferation markers ki67, mcm2 and geminin, in early breast cancer, and their putative prognostic value
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513675/
https://www.ncbi.nlm.nih.gov/pubmed/26205655
http://dx.doi.org/10.1186/s12885-015-1531-3
work_keys_str_mv AT joshishalaka digitalimagingintheimmunohistochemicalevaluationoftheproliferationmarkerski67mcm2andgeminininearlybreastcancerandtheirputativeprognosticvalue
AT watkinsjohnathan digitalimagingintheimmunohistochemicalevaluationoftheproliferationmarkerski67mcm2andgeminininearlybreastcancerandtheirputativeprognosticvalue
AT gazinskapatrycja digitalimagingintheimmunohistochemicalevaluationoftheproliferationmarkerski67mcm2andgeminininearlybreastcancerandtheirputativeprognosticvalue
AT brownjohnp digitalimagingintheimmunohistochemicalevaluationoftheproliferationmarkerski67mcm2andgeminininearlybreastcancerandtheirputativeprognosticvalue
AT gillettcheryle digitalimagingintheimmunohistochemicalevaluationoftheproliferationmarkerski67mcm2andgeminininearlybreastcancerandtheirputativeprognosticvalue
AT grigoriadisanita digitalimagingintheimmunohistochemicalevaluationoftheproliferationmarkerski67mcm2andgeminininearlybreastcancerandtheirputativeprognosticvalue
AT pindersarahe digitalimagingintheimmunohistochemicalevaluationoftheproliferationmarkerski67mcm2andgeminininearlybreastcancerandtheirputativeprognosticvalue